Enterprise Value

272.9M

Cash

148.6M

Avg Qtr Burn

-29.38M

Short % of Float

16.21%

Insider Ownership

10.20%

Institutional Own.

66.86%

Qtr Updated

03/31/24


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
XPOVIO (Selinexor) (XPO1 inhibitor) Details
Multiple myeloma, Diffuse large B cell lymphoma, Cancer

Approved

Quarterly sales

XPOVIO (Selinexor) (XPO1 inhibitor) + ruxolitinib Details
Myelofibrosis

Big Mover™

Susp. Mover™

Phase 3

Data readout

Phase 3

Data readout

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Endometrial cancer, Cancer

Big Mover™

Susp. Mover™

Phase 3

Data readout

XPOVIO (Selinexor) Details
Myelofibrosis, Primary immune thrombocytopenia

Phase 2

Data readout

Phase 2

Data readout

Eltanexor Details
Myelodysplastic syndrome, Blood cancer

Phase 2

Update

Failed

Discontinued

Failed

Discontinued

XPOVIO (Selinexor) (XPO1 inhibitor) Details
Rare diseases, Liposarcoma, Cancer

Failed

Discontinued

Failed

Discontinued

Failed

Discontinued